COMMUNIQUÉS West-GlobeNewswire
-
New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
29/06/2026 -
Cannabix Technologies Announces First BreathLogix Alcohol Device Deployment to West Africa for Mining Sector
29/06/2026 -
Achieve Life Sciences Joins Russell 2000® Index
29/06/2026 -
Acentra Health Executives Meghan Harris and Verlon Johnson Recognized on Becker’s Healthcare’s 2026 Women in Health IT to Know List
29/06/2026 -
SPR Wins Fifth Consecutive Northeast Ohio Top Workplaces Award
29/06/2026 -
SoldierStrong Donates Life-Changing ExoSym® Device to Marine Corps Veteran and Former Police Officer
29/06/2026 -
TOMI Environmental Solutions Announces Definitive Agreement to Merge with Carbonium Core
29/06/2026 -
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
29/06/2026 -
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
29/06/2026 -
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
29/06/2026 -
Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
29/06/2026 -
Tria Federal Earns Three Positions on NASA SEWP VI Government-Wide IT Contract
29/06/2026 -
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
29/06/2026 -
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
29/06/2026 -
New Video Series “Ahead of Alzheimer’s” Launches Focused on a Renewed Look at Early Alzheimer’s Detection and Preventive Brain Health Care
29/06/2026 -
Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)
29/06/2026 -
TerrAscend Files Preliminary Proxy Statement for Special Meeting of Shareholders in Preparation for Uplisting to US Exchange
29/06/2026 -
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
29/06/2026 -
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
29/06/2026
Pages